DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression

Information source: Mclean Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: MDD; Citalopram; Major Depressive Disorder

Intervention: citalopram (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Mclean Hospital

Official(s) and/or principal investigator(s):
Brian P. Brennan, M.D., Principal Investigator, Affiliation: Mclean Hospital

Overall contact:
Erin Ryan, B.A., Phone: 617-855-2984

Summary

Primarily, this study seeks to evaluate whether citalopram treatment is associated with an increase in the Glutamine (Gln)/Glutamate (Glu) ratio in the anterior cingulate cortex (ACC) from baseline to day 3 of treatment. Additionally, this study would like to examine whether citalopram treatment is associated with an increase in the Gln/Glu ratio in the ACC from baseline to day 7 of treatment.

Clinical Details

Official title: Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Gln/Glu ratio in the rostral anterior cingulate cortex (rACC) from baseline to day 3 of treatment.

Secondary outcome: Gln/Glu ratio in the rACC from baseline to day 7 of treatment

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Male or female age ≥ 18 and ≤ 65 2. Meets DSM-IV criteria for MDD 3. Current score of ≥ 18 on the 21-item Hamilton Depression Rating Scale (HAM-D). Exclusion Criteria: 1. Unwillingness or inability to provide written informed consent. 2. Current suicidal ideation 3. Active psychotic symptoms 4. Lifetime history of bipolar disorder, schizophrenia, or OCD 5. Failed treatment with an adequate trial of ≥ 2 antidepressants during the current major depressive episode ("failure" will be defined as ≤ 50% subjective improvement, and an "adequate trial" will be defined as at least 4 weeks of treatment using at least the minimum dose of the antidepressant recommended by the manufacturer in product labeling) 6. DSM-IV diagnosis of alcohol or substance dependence, with the exception of nicotine dependence, within three months prior to screening 7. Any history of treatment with electroconvulsive therapy 8. Positive urine toxicology screen for any drug of abuse or excluded medication at screening. Opiate pain medication being taken for a medical condition is exempt from needing a negative opiate screen. 9. Clinically significant medical or neurologic disease, as judged by the principal investigator, which would increase the risk to the participant or interfere with interpretation of results 10. Female participants with a positive urine pregnancy test at screening 12. Pregnancy. Females of childbearing potential must be using an effective contraceptive method (e. g., abstinence, prescription oral contraceptives, contraceptive injections, double-barrier method, male partner sterilization). 13. Any screening laboratory abnormality deemed clinically significant by the investigator 14. A QTc interval on screening ECG of ≥ 450 msec. 15. Use of any excluded medications (see Section 6. 7 below) that cannot be discontinued during the screening phase 16. Previous failure to respond to treatment with citalopram that would, in the judgment of the investigator, constitute an adequate trial in MDD 17. Treatment with any investigational medications within 30 days prior to screening 18. Any contraindications to having an MRI scan, including cardiac pacemakers, metal vascular clips or stents, artificial heart valves, certain kinds of prostheses, brain stimulator devices, implanted drug pumps, ear implants, eye implants or known metal fragments in eyes, exposure to shrapnel or metal filings (wounded in military combat, sheetmetal workers, welders, and others), transdermal drug delivery systems, and certain tattoos with metallic ink 19. Left-handedness

Locations and Contacts

Erin Ryan, B.A., Phone: 617-855-2984

McLean Hospital, Belmont, Massachusetts 02478, United States; Recruiting
Erin Ryan, B.A., Phone: 617-855-2984
Brian P. Brennan, M.D., Principal Investigator
Additional Information

Starting date: March 2012
Last updated: December 15, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017